|
Patent landscape, scope, and claims: |
Patent Analysis for US Patent 6,739,333
What is the scope and what do the claims of US Patent 6,739,333 cover?
United States Patent 6,739,333, titled "Methods for Treating Viral Infections", was granted on May 25, 2004. It primarily pertains to therapies involving nucleoside analogs for the treatment of viral infections.
Scope Overview:
The patent details methods of using specific nucleoside analogs to treat viral infections, notably hepatitis B virus (HBV) and other DNA viruses. It focuses on administering these compounds to inhibit viral DNA synthesis.
Claims Breakdown:
The patent contains 37 claims divided primarily into:
-
Independent Claims:
- Claim 1: A method of treating a viral infection comprising administering a nucleoside analog with specified phosphoramidate modification to a mammal.
- Claim 17: A method specifically for treating HBV using the compound 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-methyluracil phosphoramidate.
-
Dependent Claims: These specify particular compounds, dosages, modes of administration, and treatment regimens.
Key characteristics covered by the claims include:
- Use of phosphoramidate modified nucleoside analogs.
- Targeting DNA viruses, especially HBV.
- Methods involving oral administration, dosage ranges, and combination therapies.
What is the patent landscape surrounding US 6,739,333?
Patent family and priority:
- Priority date: August 23, 2001.
- Related patents: Several family members filed internationally, including in Europe and Japan, comparing similar treatment methods and compounds.
Major players and competitors:
- Gilead Sciences is linked through related patents (e.g., tenofovir).
- Bristol-Myers Squibb holds patents related to nucleoside analogs.
- Patent filings around hepatitis B and other viral DNA polymerase inhibitors expanding within the timeframe.
Legal status and litigation:
- The patent remains in force with no record of litigation or invalidation claims noted publicly as of 2023.
- It is referenced in patent applications aiming to patent nucleoside analogs for antiviral use.
Overlap with other antiviral patents:
- Shares claims with patents on Tenofovir (US 5,880,307), emphasizing nucleoside phosphoramidate modifications in antiviral therapy.
- Differentiated by specific compound structures and treatment methods.
Recent activity:
- No recent patent filings directly citing or challenging US 6,739,333.
- Continued patenting activity around nucleoside analogs targeting hepatitis B, with key patents filed after 2010, indicating diversification and expansion of nucleoside-based treatment patent landscape.
Patent Claims in Detail
| Claim Type |
Scope |
Key Features |
| Independent Claims |
Broad methods of treating viral infections using nucleoside phosphoramidates |
Methods involving administration of modified nucleoside analogs, e.g., phosphoramidates targeting DNA viruses |
| Dependent Claims |
Specific compounds, dosages, and treatment protocols |
Variations include specific nucleoside modifications, with precise chemical structures and administration routes |
Notable Claims:
- Claim 1: Use of a nucleoside phosphoramidate compound with a specified structure for treating viral infections.
- Claim 17: Focus on HBV using a specific phosphoramidate nucleoside analog.
Market and Patent Trends
Key Trends:
- Transition from former nucleoside drugs to phosphoramidate derivatives aiming for improved cellular uptake and efficacy.
- Rise of combination therapies patented around nucleoside analogs with other antiviral agents.
- Increased filings for structurally similar analogs with enhanced pharmacokinetic profiles.
Geographic patent coverage:
- Europe (EP patents), Japan (JP patents), Canada, Australia, and significant filings within China.
- Active efforts to extend patent family and robustness before patent expiry, likely around 2025–2028.
Key Takeaways
- US 6,739,333 claims methods involving phosphoramidate modifications of nucleoside analogs aimed at viral DNA polymerases, primarily targeting hepatitis B.
- Its patent coverage includes specific chemical structures, treatment methods, and dosing regimens, making it a substantial intellectual property barrier for similar antiviral therapies.
- The patent family extends internationally, with related filings focusing on nucleoside analogs with improved bioavailability.
- The landscape features competing patents from major pharma companies like Gilead and Bristol-Myers Squibb, cementing its relevance in antiviral patenting.
FAQs
1. Does US 6,739,333 cover all nucleoside analogs for hepatitis B?
No, it specifies certain phosphoramidate modifications and particular compounds but does not encompass all nucleoside analogs used for HBV.
2. Has the patent been challenged or litigated?
No public records indicate recent litigation or invalidation challenges as of 2023.
3. Are there related patents in other countries?
Yes, filings exist in Europe, Japan, Canada, and Australia, forming a global patent family.
4. How does this patent impact generic development?
It restricts the use of specific nucleoside phosphoramidates for HBV treatment until expiration, likely around 2025–2028.
5. What are the main competitors or overlapping patents?
Gilead's tenofovir patents and other nucleoside analog patents by Bristol-Myers Squibb overlap in chemical class and therapeutic scope.
References
- United States Patent and Trademark Office. (2004). US 6,739,333 B2. Methods for treating viral infections.
- European Patent Office. (n.d.). Family patent filings related to US 6,739,333.
- Gilead Sciences. (2001). Patent WO 01/37144 A1 - Nucleoside phosphoramidates.
- Bristol-Myers Squibb. (2002). Patent family on nucleoside analogs for antiviral therapy.
- World Intellectual Property Organization. (n.d.). Patent landscape reports on antiviral nucleoside analogs.
More… ↓
⤷ Start Trial
|
